Effects of Ginkgo biloba in dementia: systematic review and meta-analysis

Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/4881
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/4924
dc.contributor.author Weinmann, Stefan
dc.contributor.author Roll, Stephanie
dc.contributor.author Schwarzbach, Christoph
dc.contributor.author Vauth, Christoph
dc.contributor.author Willich, Stefan N.
dc.date.accessioned 2019-05-27T11:49:51Z
dc.date.available 2019-05-27T11:49:51Z
dc.date.issued 2010
dc.identifier.citation Weinmann, S.; Roll, S.; Schwarzbach, C.; Vauth, C.; Willich, S.N.: Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. In: BMC Geriatrics 10 (2010), 14. DOI: https://doi.org/10.1186/1471-2318-10-14
dc.description.abstract Background: The benefit of Ginkgo biloba has been discussed controversially. The aim of this review was to assess the effects of Ginkgo biloba in Alzheimer's disease as well as vascular and mixed dementia covering a variety of outcome domains. Methods: We searched MEDLINE, EMBASE, the Cochrane databases, CINAHL and PsycINFO for controlled trials of ginkgo for Alzheimer's, vascular or mixed dementia. Studies had to be of a minimum of 12 weeks duration with at least ten participants per group. Clinical characteristics and outcomes were extracted. Meta-analysis results were expressed as risk ratios or standardized mean differences (SMD) in scores. Results: Nine trials using the standardized extract EGb761 (R) met our inclusion criteria. Trials were of 12 to 52 weeks duration and included 2372 patients in total. In the meta-analysis, the SMDs in change scores for cognition were in favor of ginkgo compared to placebo (-0.58, 95% confidence interval [CI] -1.14; -0.01, p = 0.04), but did not show a statistically significant difference from placebo for activities in daily living (ADLs) (SMD = -0.32, 95% CI -0.66; 0.03, p = 0.08). Heterogeneity among studies was high. For the Alzheimer subgroup, the SMDs for ADLs and cognition outcomes were larger than for the whole group of dementias with statistical superiority for ginkgo also for ADL outcomes (SMD = -0.44, 95% CI -0.77; -0.12, p = 0.008). Drop-out rates and side effects did not differ between ginkgo and placebo. No consistent results were available for quality of life and neuropsychiatric symptoms, possibly due to the heterogeneity of the study populations. Conclusions: Ginkgo biloba appears more effective than placebo. Effect sizes were moderate, while clinical relevance is, similar to other dementia drugs, difficult to determine. eng
dc.language.iso eng
dc.publisher London : BioMed Central
dc.relation.ispartofseries BMC Geriatrics 10 (2010)
dc.rights CC BY 4.0 Unported
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject Dementia eng
dc.subject Cholinesterase Inhibitor eng
dc.subject Standardize Mean Difference eng
dc.subject Ginkgo Extract eng
dc.subject Montgomery Asberg Depression Rate Scale eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Effects of Ginkgo biloba in dementia: systematic review and meta-analysis
dc.type Article
dc.type Text
dc.relation.issn 1471-2318
dc.relation.doi https://doi.org/10.1186/1471-2318-10-14
dc.bibliographicCitation.issue 14
dc.bibliographicCitation.volume 10
dc.bibliographicCitation.firstPage 14
dc.description.version publishedVersion
tib.accessRights frei zug�nglich

Files in this item

This item appears in the following Collection(s):

Show simple item record


Search the repository


My Account

Usage Statistics